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Background: Lup-20(29)-en-3H-ol (Lupeol), a dietary triterpene, has been shown to possess multiple pharmacological
activities including anti-tumor effects
Methods: In the current study, we noted that low doses of lupeol (<40 μM) promoted the growth of hepatocellular
carcinoma (HCC) cells with a significant activation of the PI3-kinase/Akt signaling pathway. We further investigated the
combined anti-tumor effect of lupeol and S14161, a newly identified PI3-Kinase inhibitor in vitro and in vivo
Results: The results demonstrated that lupeol and S14161 could exert a synergistic antitumor effect resulting in
chemo-sensitization of HCC to low doses of lupeol. Using an in vivo HCC model, we further demonstrated that lupeol
and S14161 synergistically inhibited tumor growth without any adverse effects on body weight
Conclusion: Our studies showed that the activation of PI3-kinase/Akt pathway resulted in the tumor-promoting effect
with low doses of lupeol. Combining PI3-kinase inhibitor with lupeol could synergistically augment the anti-tumor
effect of lupeol and might be an applicable strategy for HCC therapy.
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Hepatocellular carcinoma (HCC) becomes the fifth most
frequent cancer and the third most common cause of
cancer-related mortality in the world, preceded only by
lung cancer and stomach cancer [1-4]. Asian countries
account for nearly 78% of the roughly 600,000 cases of
HCC reported globally each year [5]. Although the prognosis
of patients with HCC has marginally improved, a historical
5-year survival rate worldwide is still less than 5%, mainly
because of a high potential for vascular invasion, metastasis,
and recurrence even after surgical resection [6]. Various
approaches have been developed, curative effect is far from
perfect due to the highly chemoresistant nature of the tumor* Correspondence: hliu@suda.edu.cn
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reproduction in any medium, provided the orand the toxicity of chemotherapeutic agents [4,7-11].
Therefore, efforts are urgently needed to explore more
effective therapeutic agents for treating HCC.
There is a growing interest in dietary substances
obtained from natural products because of their minimal
toxicity. Emphasis has been placed on triterpenes, due to
their wide spectrum of biological activities. They could
selectively or preferentially eliminate cancer cells by
inhibiting cell cycle progression and by causing apoptosis
[12]. One such triterpene which has gained wide attention
is lupeol [Lup-20(29)-en-3β-ol]. Extensive research over
the last three decades has revealed various important
pharmacological activities of lupeol under in vitro and in vivo
conditions, including anti-inflammation, anti-arthritis,
anti-diabetes, anti-heart diseases, anti-renal toxicity,
anti-hepatic toxicity and anti-cancer [13-15]. Lupeol
has been reported not only to induce differentiation and
inhibit the growth of melanoma and leukemia cells
[16-19], but also to inhibit tumor promotion in two-stage
mouse skin carcinogenesis through modulating NF-κBThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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growth and induce apoptosis in both prostate [21] and
pancreatic cancers [22]. Recent studies have also shown
that lupeol induced apoptosis of HCC cells SMMC7721
by down-regulating death receptor 3 (DR3) [23], and also
had in vivo and in vitro therapeutic effect for HCC
by targeting liver tumor-initiating cells (T-ICs) through
modulating PTEN-Akt-ABCG2 pathway [24]. Our previous
work also proved anti-HCC efficacy of lupeol and a com-
bined effect with rTRAIL in inducing chemo-sensitization
of HCC [25]. Meanwhile, lupeol exhibited very low toxicity.
Lupeol administered orally in a dose of 2 g/kg body weight
has been reported to produce no adverse effects in rats and
mice [15]. However, the toxicity has not been examined in
human. On the other hand, our previous results [25]
showed that lupeol could also reduce the cell viability of
the normal human liver cells with an IC50 of 90 μmol/L,
suggesting that lupeol could exert toxic effect on normal
cells. Lupeol concentrations of less than 30 μmol/L do not
affect the normal liver cell viability. Lupeol has also been
shown by numerous studies to have anti-inflammatory
activity in rats and mice at the dose of 25-200 mg/kg
[26-28]. Therefore, high doses of lupeol could also inhibit
anti-tumor immune responses. Therefore, low dose of
lupeol is desirable because it can minimize the toxicity to
normal cells and the immune suppressive effect of lupeol if
the anti-tumor effect could also be achieved. In the current
study, we found that low doses of lupeol could promote
tumor growth in vitro and had a very minimal effect on
HCC in vivo. We further exploited the underlying
mechanisms and demonstrated a synergistic effect of
combination treatment with low doses of lupeol and
PI3K inhibitor in HCC, which made low dose lupeol
possible for tumor treatment.
PI3K/Akt pathway plays an important role in various
types of cancers, including HCC. Akt is important in
protecting the cells from various types of apoptotic
stimuli and regulating cell proliferation and cell cycle
by interacting, either directly or indirectly, with numerous
other regulatory proteins [29,30]. Blockage of Akt signaling
by some reagents results in programmed cell death and
growth inhibition of tumor cells [31-34]. Therefore, targeted
therapies against specific components of this pathway are
expected to be efficacious as single agents or in combination
in a variety of human cancers. Up to now, many inhibitors
of PI3K/Akt pathway have been developed. LY294002 and
wortmannin both target the catalytic site p110 of PI3K. Due
to their unfavorable pharmaceutical properties, toxicity,
and crossover inhibition of other lipid and protein kinases,
they were not extensively used in clinical trials [35].
Recently, 8-ethoxy-2-(4-fluorophenyl)3-nitro-2H-chromene
(S14161) showed potent anti-leukemia and anti-myeloma
activity in vitro and inhibited in vivo tumor growth [36].
S14161 has been shown to have no effect on the cell viabilityof the normal hematopoietic cells with the concentra-
tion as high as 25 μmol/L and no effect on body
weight with 100 mg/kg/day intraperitoneal injection for
10 days. The effect of S14161 on HCC has not been
determined.
In the present study, we unexpectedly discovered that
low doses of lupeol promoted cell growth of HCC cells
through the activation of PI3K/Akt pathway. To further
improve the anti-tumor efficacy of lupeol, we combined
lupeol treatment with S14161. The results demonstrated
that lupeol and S14161 could exert synergistic effects
inhibiting tumor growth in vitro and in vivo. Our results
provided evidence that PI3-kinase/Akt signaling pathway
activation promoted tumor growth by low doses of lupeol.
Combining PI3K inhibition and lupeol treatment could
provide safer and more effective anti-tumor therapeutic
regimen.
Methods
Cell lines and culture
Human HCC cell lines, HepG2 and SMMC7721, were
purchased from Cell Bank, Chinese Academy of Sciences
(Shanghai, China). They were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) with high glucose
(Gibco BRL, Grand Island, NY) supplemented with 10%
heat-inactivated fetal bovine serum (Gibco BRL, Grand
Island, NY), 10mg/ml penicillin G and 50 μg/ml treptomy-
cin (Shanghai Sangon Biological Engineering Technology &
Services Co., Shanghai, China) at 37°C in a humidified
atmosphere containing 5% CO2. Cells were harvested using
0.25% trypsin/EDTA (Invitrogen, Carlsbad, CA).
Antibodies and reagents
Lupeol was purchased from Sigma-Aldrich (St. Louis, MO)
and a stock solution of lupeol (30 mmol/L) was prepared
by resuspension in warm alcohol and dilution in DMSO
at 1:1 ratio.
Antibodies against β-actin was purchased from BD
Pharmingen (Franklin Lakes, NJ). Antibodies against
PI3/K p110δ, phospho-Akt (Thr308) and total-Akt were
purchased from Cell Signal Technology (Boston, MA).
Cytoplasmic Protein Extraction Kit and BCA Protein Assay
Kit were purchased from Beyotime (Nantong, China).
Cell viability assay
The effect of Lupeol and/or S14161 on cell viability was
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazoliumbromide (MTT) assay. Cells were plated at
3 × 103 per well in 100 μl of complete culture medium in
96-well cell culture plates 24 h before the assay. Then
cells were treated with different concentrations of
related compounds for 48 h. Each concentration was
repeated in 5 wells. After incubation for 48 h, 20 μl MTT


























































Figure 1 Low doses of lupeol promoted the viability and
activated the PI3K/Akt pathway in HCC cell lines. (A) The
chemical structure of lupeol. (B) MTT assay was performed to
measure cell viability of HepG2 and SMMC7721 cells at 48 h after
lupeol treatment. (C) PI3K subunit p110 protein expression and the
phosphorylated level of Akt was measured by western blot in
SMMC7721 cells treated with low doses of lupeol at doses of
10, 20, 30 μmol/L for 48 h. Equal loading was confirmed by stripping
immunoblots and re-probing for β-actin. The quantification results
were also shown and the statistical analysis was performed. Data
shown were representatives of three independent experiments.
* p < 0.05.
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DMSO was added to each well. The absorbance was
recorded on a microplate reader at the wavelength of
490 nm. The effect on cell growth inhibition was
assessed as percent cell proliferation inhibition wherein
vehicle-treated cells were taken as 0% inhibition.
Protein preparation and western blot analysis
HCC cells (50% confluent) were treated with 10, 20,
30 μmol/L of lupeol, 1 μmol/L, 3 μmol/L of S14161 alone or
in combination with 20 μmol/L lupeol for 48 h in 10% fetal
bovine serum-DMEM. Cells were then harvested and cell
lysates were prepared using Cytoplasmic Protein Extraction
Kit (Beyotime, Nantong, China) and stored at -80°C for later
use. The protein content in the lysates was measured by
BCA Protein Assay Kit (Beyotime, Nantong, China). For
Western blot analysis, 25 μg of protein were resolved over
12% tris-glycine polyacrylamide gels under nonreduced
conditions, transferred onto PVDF membranes, and
subsequently incubated in blocking buffer (5% nonfat
dry milk in PBS) overnight at 4°C. The blots were
incubated with appropriate primary antibody, washed, and
incubated with horseradish peroxidase (HRP)-conjugated
secondary antibody (Dako, Carpinteria, CA). The blots
were detected with chemiluminescence (ECL-Kit,
Beyotime, Nantong, China) followed by autoradiography.
Relative amounts of proteins were quantified by absorbance
analysis. The level was normalized to β-actin, a domestic
loading control.
Animal studies
A total of 2 × 106 SMMC7721 cells suspended in 200 μl
PBS were inoculated s.c. into the right flank of 6- to
8-week-old female athymic nude mice (BALB/c-nu/nu).
Treatment was started once the size of the xenograft
reached approximately 4 × 4 mm. The mice were
randomly assigned into four groups, each consisting
of 6 mice. They were treated with intraperitoneal
injection for 3 weeks of either (1) 20 mg/kg lupeol
in 0.1 mL of corn oil, (2) 20 mg/kg S14161 in 0.1 mL corn
oil, (3) 20 mg/kg lupeol plus 20 mg/kg S14161 in 0.1
mL corn oil, or (4) 0.1 mL of corn oil alone as the
control group. Lupeol was injected three times/week
(total 9 times), while S14161 was injected once/day
for five continuous days/week (total 15 times). Animals in
all the groups were observed for any apparent signs
of toxicity, such as weight loss or mortality during
the entire period of study. Tumor growth was
assessed weekly by measuring the two greatest per-
pendicular tumor dimensions. Tumor volume was cal-
culated by the formula: tumor volume (mm3) =
[tumor length (mm) × tumor width (mm)2]/2 (34). All
animals were sacrificed at the end of 5 weeks. Animal
studies were carried out in accordance with the
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specifically approved by the Ethical Committee of
Soochow University. The body weight and the tumor
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Figure 2 Synergistic anti-HCC effect of S14161 and lupeol in vitro. (A)
measure cell growth inhibition rate of SMMC7721 at 48 h after S14161 trea
rate of (C) SMMC7721 cells and (D) HepG2 cells 48 h after treated with lup
level of PI3-kinase subunit p110 and the phosphorylated level of Akt in (E)
blot after single or combination treatment with low dose of lupeol (20 μm
confirmed by stripping immunoblots and re-probing for β-actin. Statistical
three independent experiments. * p < 0.05.Statistical analysis
All data represents at least three independent experi-
ments and results were shown as mean ± SD. Statistical
differences between two groups were determined by
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The chemical structure of S14161. (B) MTT assay was performed to
tment. MTT assay was performed to measure cell growth inhibition
eol alone or in combination with 1 or 3 μmol/L S14161. Expression
SMMC7721 cells and (F) HepG2 cells were measured by western
ol/L) and S14161 (1 μmol/L or 3 μmol/L) for 48 h. Equal loading was
analysis was performed. Results shown were the representatives of
Liu et al. Cancer Cell International 2013, 13:108 Page 5 of 7
http://www.cancerci.com/content/13/1/108was applied for multiple group comparison. A significant
difference was considered as p < 0.05.
Results
Low doses of lupeol promoted the viability and activated
the PI3K/Akt pathway in HCC cell lines
We and others have previously reported that lupoel could
inhibit cell growth of HCC cells in a dose dependent manner
[23,25]. Meanwhile, we have also noted that low concen-
trations of lupeol promoted the viability of HCC cells
(Figure 1B). Studies have shown that PI3K/Akt pathway plays
an important role in chemical-resistance of various cancers.
Western blotting revealed that the protein levels of PI3K
p110 and the total and phosphorylated level of Akt were in-
creased with low dose lupeol treatment, especially at 10 and
20 μmol/L (Figure 1C). These data suggested that low doses
of lupeol could activate PI3K/Akt pathway, which might be
the reason for its promoting effect on HCC cell viability.
Synergistic anti-HCC effect of S14161 and lupeol in vitro
To sensitize HCC cells to low doses of lupeol therapy,
we evaluated the effect of combining PI3K inhibitor and
lupeol treatment. S14161 (Figure 2A) is a newly reported
PI3K inhibitor [36], and its chemical structure is similar
to that of LY294002, a well-known PI3K inhibitor. Based
on the dose–response curves, the IC50 of S14161 was
calculated as 4 μmol/L for SMMC7721 (Figure 2B). The
concentration of 1 μmol/L (no inhibition) and 3 μmol/L
(30% inhibition) were used in the following experiments.
To examine the effect of combined lupeol and S14161
treatment on HCC cells, SMMC7721 cells were treatedA B
p<0.05 p<0.0
Figure 3 Synergistic anti-HCC effect of S14161 and lupeol in vivo. (A)
lupeol and 20 mg/kg S14161. SMMC7721 xenograft nude mice were treate
one more week. Tumors were measured and tumor volumes were calculated
treatment with 20 mg/kg lupeol and 20 mg/kg S14161. (C) Body weights of m
treatment. Values represent means ± SD of n = 6. Results shown were the repby lupeol with doses ranging from 10 to 100 μmol/L at
the presence of 1 or 3 μmol/L S14161 (Figure 2C).
Interestingly, S14161 at 1 and 3 μmol/L enhanced the
cell growth inhibition in SMMC7721 cells treated by
lupeol. The IC50 was significantly reduced when the
cells were treated with both lupeol and S14161 (lupeol
alone: 44.9 μmol/L, lupeol + 1 μmol/L S14161: 40.1 μmol/L,
lupeol + 3 μmol/L S14161: 27.9 μmol/L). A synergistic ef-
fect on HCC cell growth inhibition was observed with the
combination treatment, especially with combined low dose
lupeol and S14161 (Figure 2C). Similar results were also
observed with HepG2 cells (Figure 2D).
We then investigated the activity of the PI3K/Akt pathway
with single or combined treatment of low dose lupeol and
S14161. As shown in Figure 2E, the expression levels of
PI3K subunit p110 and phosphorylated Akt were increased
with the 20 μmol/L lupeol treatment. Not surprisingly, the
PI3K inhibitor, S14161 slightly reduced the level of phos-
phorylated Akt at 1 and 3 μmol/L concentrations and this
reduction was maintained when S14161 was combined with
lupeol treatment. The phosphorylated Akt was also signifi-
cantly reduced with 3 μmol/L S14161 and the combined
treatment with lupeol in HepG2 cells (Figure 2F). These
results suggested that PI3K/Akt pathway activation by low
doses of lupeol could be reversed by combinational
treatment with PI3K inhibitor, S14161.
Synergistic anti-HCC effect of S14161 and lupeol in vivo
A nude mouse model of HCC was used to assess the
in vivo anti-tumor effect of S14161 and lupeol. Lupeol at
a dose of 20 mg/kg three times per week and S14161 at aC
5
Tumor volumes after single or combination treatment with 20 mg/kg
d with lupeol and/or S14161 for 3 weeks, and then were observed for
. (B) The growth inhibition rates of tumors after single or combination
ice in each group were measured every week for 5 weeks during the
resentatives of three independent experiments.
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the mice bearing established SMMC7721 tumors for 3 weeks
(Figure 3). At the end of the therapy, single therapy with
lupeol (399 ± 146 mm3) or S14161 (350 ± 123 mm3) showed
decreased tumor volumes by 14% and 25% compared to the
controls (464 ± 160 mm3), respectively (Figure 3A&B). In
addition, the combination treatment seemed to be more
effective than the single treatments. The tumor volume
was reduced by 54% (230 ± 98 mm3) compared to the
controls. Therefore, the combination treatment of S14161
and lupeol synergistically promoted the anti-tumor effects
of either treatment alone. To examine the side effects of
the combination therapy, the body weights were recorded
each weak, and no significant differences in body weights
were detected among each treatment groups (Figure 3C).
The results demonstrated that combining S14161 and
lupeol treatment could synergistically inhibit the HCC
tumor growth in vivo with little toxicity.
Discussion and conclusion
Previous studies have focused on the anti-tumor effects
and mechanisms of lupeol in HCC. Studies have shown
that lupeol induced apoptosis of SMMC7721 cells by
down-regulating death receptor 3 (DR3) [23]. Lupoel
could also target liver tumor-initiating cells (T-ICs)
though modulating PTEN-Akt-ABCG2 pathway [24].
Our previous work also proved anti-HCC efficacy of
lupeol and a combined effect with rTRAIL in inducing
chemo-sensitization of HCC [25]. In this report, we first
described the tumor-promoting role of lupeol at low
doses. We discovered that PI3K/Akt pathway was
activated by low concentrations of lupeol treatment. We
further demonstrated that inhibition of the PI3K/Akt
pathway enhanced the antitumor effect of lupeol and the
combination therapy of lupeol and S14161 synergistically
promoted therapeutic effect on HCC.
PI3K/Akt pathway is critically involved in the control of
cell growth, cell survival and malignant transformation
[37]. Blockage of PI3K/Akt signaling pathway results in
programmed cell death and growth inhibition of tumor
cells. An Akt inhibitor, perifosine, showed synergistic
antitumor effect with cisplatin in HepG2 cells through
down-regulating the expression of Bcl-2 and up-regulating
the level of Bax [34]. A PI3K inhibitor, LY294002, also
showed synergistic antitumor effect with cisplatin in
human pancreatic cancer cells by down-regulating the
phosphorylated levels of Bad protein [38]. Recently,
S14161 showed potent anti-leukemia and anti-myeloma
activity in vitro and inhibited in vivo tumor growth
through inhibiting the activity of PI3K [36]. Lupeol has also
been reported to inhibit skin cancer in CD-1 mice through
inhibition of TPA-induced activation of PI3K and phos-
phorylated level of Akt at Thr308 [20]. However, this study
was performed in vivo at relatively high concentrations oflupeol (1 or 2 mg/mouse). We have also observed inhib-
ition of Akt phosphorylation at 50 μmol/L lupeol or higher
in vitro (data not shown). On the other hand, low doses of
lupeol could promote PI3K/Akt pathway, especially at 10-
20 μmol/L concentrations, which suggested that lupeol
could function through different targets that had opposite
effects on PI3K/Akt pathway with different affinities.
Many natural products have been found to have
multiple targets, which allow them to have multiple
pharmacological activities. Lupeol has been shown to
exhibit anti-inflammatory, anti-microbial, anti-protozoal,
anti-tumor, anti-angiogenic and cholesterol lowering
activities [39]. The mechanism of the anti-tumor effect of
lupeol was initially thought to be inhibiting NFκB [22].
Wnt/β-catenin pathway was also found to be suppressed
by lupeol in treating human melanoma cells [19]. Lupoel
could also target liver tumor-initiating cells (T-ICs) though
modulating PTEN-Akt-ABCG2 pathway [24]. Recently,
lupeol has been found to be a novel androgen receptor
inhibitor that may be effective in treating prostate
cancer [40]. Therefore, many signaling pathways may
work together to exert the anti-tumor effect of lupeol.
We propose based on our findings that lupeol may have a
target with high affinity that promotes PI3K/Akt activities
and tumor cell growth at low doses. At high concentrations
of lupeol, the low affinity targets of lupeol dominate and
regulate the signaling pathways that eventually lead to the
suppression of tumor cell growth.
Taken together, our results demonstrated that lupeol
could target to activate PI3-kinase/Akt pathway and
promote tumor cell growth at low doses. Combination
therapy of lupeol and a PI3-kinase inhibitor, S14161,
could synergistically enhance the antitumor effect of
lupeol in vitro and in vivo. Therefore, our results support
the notion that lupeol combining with PI3-kinase inhibitor
may provide more effective anti-HCC regimen.
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